Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 4/20 | 0.53 |
| ▸ | MMP8 | P22894 | 2/20 | 0.53 |
| ▸ | MME | P08473 | 1/20 | 0.49 |
| ▸ | TSHR | P16473 | 2/20 | 0.49 |
| ▸ | GAA | P10253 | 1/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.48 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.48 |
| ▸ | CA12 | O43570 | 1/20 | 0.48 |
| ▸ | CA1 | P00915 | 1/20 | 0.48 |
| ▸ | CA2 | P00918 | 1/20 | 0.48 |
| ▸ | CA3 | P07451 | 1/20 | 0.48 |
| ▸ | CA4 | P22748 | 1/20 | 0.48 |
| ▸ | CA6 | P23280 | 1/20 | 0.48 |
| ▸ | CA5A | P35218 | 1/20 | 0.48 |
| ▸ | CA7 | P43166 | 1/20 | 0.48 |
| ▸ | CACNA1C | Q13936 | 1/20 | 0.48 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.48 |
| ▸ | CA9 | Q16790 | 1/20 | 0.48 |
| ▸ | CA13 | Q8N1Q1 | 1/20 | 0.48 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8568656 | 0.86 | MMP8 (0.51) | KMT2AMMP8MMETSHRGAA | |
| SCHEMBL8568653 | 0.86 | MMP8 (0.51) | KMT2AMMP8MMETSHRGAA | |
| SCHEMBL526281 | 0.86 | KMT2A (0.53) | KMT2AMMP8MMETSHRGAA | |
| SCHEMBL526555 | 0.86 | KMT2A (0.53) | KMT2AMMP8MMETSHRGAA | |
| SCHEMBL23754579 | 0.84 | KMT2A (0.55) | KMT2AMMP8MMEGAAALDH1A1 | |
| SCHEMBL2936657 | 0.84 | KMT2A (0.55) | KMT2AMMP8MMEGAAALDH1A1 | |
| SCHEMBL15610313 | 0.83 | KMT2A (0.57) | KMT2AMMP8MMETSHRGAA | |
| SCHEMBL17617945 | 0.83 | KMT2A (0.56) | KMT2AGAAALDH1A1MEN1 | |
| SCHEMBL11380823 | 0.83 | GAA (0.54) | KMT2AMMP8GAAALDH1A1MEN1 | |
| SCHEMBL10638067 | 0.81 | KMT2A (0.53) | KMT2AMMP8MMEALDH1A1CA12 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3567027-B1 | METHOD FOR PRODUCING N-BENZYL-2-BROMO-3-METHOXYPROPIONAMIDE AND INTERMEDIATES THEREOF | API CORP (JP) | 2022-01-19 | — | — | EP | claimed |
| US-11136287-B2 | Method for producing n-benzyl-2-bromo-3-methoxypropionamide and intermediates thereof | API CORPORATION (JP) | 2021-10-05 | — | — | US | claimed |
| US-20200115322-A1 | METHOD FOR PRODUCING N-BENZYL-2-BROMO-3-METHOXYPROPIONAMIDE AND INTERMEDIATES THEREOF | API CORPORATION (JP) | 2020-04-16 | — | — | US | claimed |
| EP-3567027-A1 | N-BENZYL-2-BROMO-3-METHOXYPROPIONAMIDE AND METHOD FOR PRODUCING INTERMEDIATE THEREOF | API Corporation (JP) | 2019-11-13 | — | — | EP | claimed |
| EP-3567027-B1 | METHOD FOR PRODUCING N-BENZYL-2-BROMO-3-METHOXYPROPIONAMIDE AND INTERMEDIATES THEREOF | API CORP (JP) | 2022-01-19 | — | — | EP | disclosed |
| US-11136287-B2 | Method for producing n-benzyl-2-bromo-3-methoxypropionamide and intermediates thereof | API CORPORATION (JP) | 2021-10-05 | — | — | US | disclosed |
| US-11136287-B2 | Method for producing n-benzyl-2-bromo-3-methoxypropionamide and intermediates thereof | API CORPORATION (JP) | 2021-10-05 | — | — | US | disclosed |
| US-20200115322-A1 | METHOD FOR PRODUCING N-BENZYL-2-BROMO-3-METHOXYPROPIONAMIDE AND INTERMEDIATES THEREOF | API CORPORATION (JP) | 2020-04-16 | — | — | US | disclosed |
| US-20200115322-A1 | METHOD FOR PRODUCING N-BENZYL-2-BROMO-3-METHOXYPROPIONAMIDE AND INTERMEDIATES THEREOF | API CORPORATION (JP) | 2020-04-16 | — | — | US | disclosed |
| EP-3567027-A1 | N-BENZYL-2-BROMO-3-METHOXYPROPIONAMIDE AND METHOD FOR PRODUCING INTERMEDIATE THEREOF | API Corporation (JP) | 2019-11-13 | — | — | EP | disclosed |
| EP-3567027-A1 | N-BENZYL-2-BROMO-3-METHOXYPROPIONAMIDE AND METHOD FOR PRODUCING INTERMEDIATE THEREOF | API Corporation (JP) | 2019-11-13 | — | — | EP | disclosed |
| WO-2018159028-A1 | N-BENZYL-2-BROMO-3-METHOXYPROPIONAMIDE AND METHOD FOR PRODUCING INTERMEDIATE THEREOF | 株式会社エーピーアイ コーポレーション | 2018-09-07 | — | — | WO | disclosed |
| US-20160081995-A1 | Selective NR2B Antagonists | BRISTOL MYERS SQUIBB CO (US) | 2016-03-24 | — | — | US | disclosed |
| US-9221796-B2 | Selective NR2B antagonists | BRISTOL-MYERS SQUIBB COMPANY (US) | 2015-12-29 | — | — | US | disclosed |
| US-20150191452-A1 | Selective NR2B Antagonists | BRISTOL-MYERS SQUIBB COMPANY | 2015-07-09 | — | — | US | disclosed |
| US-20130317109-A1 | PROCESS FOR THE PREPARATION OF LACOSAMIDE | CAMBREX KARLSKOGA AB (SE) | 2013-11-28 | — | — | US | disclosed |
| EP-2643293-A1 | PROCESS FOR THE PREPARATION OF LACOSAMIDE | Cambrex Karlskoga AB (SE) | 2013-10-02 | — | — | EP | disclosed |
| WO-2013072933-A2 | PROCESS FOR PREPARATION OF 2-ACETAMIDO-N-BENZYL-3-METHOXYPROPIONAMIDE | GLENMARK GENERICS LIMITED (IN) | 2013-05-23 | — | — | WO | disclosed |
| WO-2013072933-A2 | PROCESS FOR PREPARATION OF 2-ACETAMIDO-N-BENZYL-3-METHOXYPROPIONAMIDE | GLENMARK GENERICS LIMITED (IN) | 2013-05-23 | — | — | WO | disclosed |
| WO-2012069855-A1 | PROCESS FOR THE PREPARATION OF LACOSAMIDE | CAMBREX KARLSKOGA AB (SE) | 2012-05-31 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200115322-A1 | METHOD FOR PRODUCING N-BENZYL-2-BROMO-3-METHOXYPROPIONAMIDE AND INTERMEDIATES THEREOF | NAAA, BRD2, PAM | KMT2A 336/4885MMP8 1885/4885MME 142/4885 |
| US-20150191452-A1 | Selective NR2B Antagonists | GRIN2B, GRIN2A, GRIN3A | KMT2A 2824/4885MMP8 4044/4885MME 1271/4885 |
| US-20130317109-A1 | PROCESS FOR THE PREPARATION OF LACOSAMIDE | NAAA, APEH, DNPEP | KMT2A 551/4885MMP8 1600/4885MME 163/4885 |
| US-11136287-B2 | Method for producing n-benzyl-2-bromo-3-methoxypropionamide and intermediates thereof | NAAA, BRD2, PAM | KMT2A 336/4885MMP8 1885/4885MME 142/4885 |
| US-20160081995-A1 | Selective NR2B Antagonists | GRIN2B, GRIN2A, GRIN3A | KMT2A 2824/4885MMP8 4044/4885MME 1271/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.